Overview

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Islet Amyloid Polypeptide
Pramlintide